Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer.
Ontology highlight
ABSTRACT: Background: The outcome and tolerability of palliative second line chemotherapy for advanced pancreatic cancer (APC) in real life patients are largely unknown. Prognostic parameters for risk stratification and treatment guidance are lacking. Materials and Methods: A population based multicenter retrospective cohort study was conducted, covering all APC patients who received palliative second-line chemotherapy between 2011 and 2018 at any cancer center in the South East Region of Sweden. Primary outcome was overall survival after second-line therapy (OS2). Time to treatment failure after second-line therapy (TTF2), hematological toxicity, and unplanned hospitalizations were key secondary outcomes. A number of baseline potentially prognostic parameters were assessed. Results
SUBMITTER: Gransmark E
PROVIDER: S-EPMC7397908 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA